 Seena Aisner
Concepts (265)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 1 | 2022 | 44 | 0.760 |
Why?
| | Soft Tissue Neoplasms | 4 | 2009 | 89 | 0.600 |
Why?
| | Bone Neoplasms | 4 | 2008 | 191 | 0.530 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2017 | 959 | 0.510 |
Why?
| | Thymus Neoplasms | 3 | 2011 | 20 | 0.500 |
Why?
| | Diagnosis, Differential | 10 | 2022 | 1331 | 0.490 |
Why?
| | Lung Neoplasms | 10 | 2017 | 2159 | 0.450 |
Why?
| | Breast Neoplasms | 3 | 2022 | 1846 | 0.410 |
Why?
| | Octreotide | 2 | 2010 | 25 | 0.400 |
Why?
| | Sarcoma, Alveolar Soft Part | 2 | 2010 | 7 | 0.390 |
Why?
| | Liposarcoma | 3 | 2009 | 25 | 0.390 |
Why?
| | Prednisone | 2 | 2010 | 229 | 0.380 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2010 | 138 | 0.380 |
Why?
| | Lipoma | 2 | 2009 | 14 | 0.370 |
Why?
| | Translocation, Genetic | 3 | 2010 | 92 | 0.360 |
Why?
| | Receptor, ErbB-2 | 2 | 2010 | 300 | 0.350 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2010 | 34 | 0.340 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 63 | 0.340 |
Why?
| | Chondroblastoma | 2 | 2006 | 3 | 0.320 |
Why?
| | Biopsy, Fine-Needle | 4 | 2014 | 65 | 0.310 |
Why?
| | ErbB Receptors | 2 | 2016 | 554 | 0.300 |
Why?
| | Fibula | 1 | 2008 | 40 | 0.300 |
Why?
| | Nevus, Spindle Cell | 1 | 2007 | 1 | 0.290 |
Why?
| | Angiofibroma | 1 | 2007 | 3 | 0.290 |
Why?
| | Leiomyoma | 1 | 2008 | 44 | 0.290 |
Why?
| | Biomarkers, Tumor | 4 | 2017 | 1032 | 0.270 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2006 | 10 | 0.270 |
Why?
| | Head and Neck Neoplasms | 2 | 2012 | 427 | 0.270 |
Why?
| | Tibia | 1 | 2008 | 166 | 0.260 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2017 | 850 | 0.260 |
Why?
| | Femoral Neoplasms | 1 | 2006 | 7 | 0.260 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 170 | 0.250 |
Why?
| | Image Enhancement | 1 | 2006 | 158 | 0.250 |
Why?
| | Cheek | 1 | 2004 | 16 | 0.240 |
Why?
| | Facial Neoplasms | 1 | 2004 | 16 | 0.240 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2017 | 1356 | 0.240 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2016 | 77 | 0.230 |
Why?
| | Immunohistochemistry | 10 | 2014 | 1624 | 0.230 |
Why?
| | Microtomy | 1 | 2003 | 3 | 0.210 |
Why?
| | Middle Aged | 24 | 2019 | 26605 | 0.210 |
Why?
| | Cytological Techniques | 1 | 2003 | 24 | 0.210 |
Why?
| | Pain | 2 | 2008 | 701 | 0.210 |
Why?
| | Biopsy, Needle | 1 | 2003 | 180 | 0.200 |
Why?
| | Vulvar Neoplasms | 1 | 2022 | 10 | 0.200 |
Why?
| | Subcutaneous Tissue | 1 | 2022 | 17 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3039 | 0.200 |
Why?
| | Paclitaxel | 2 | 2014 | 190 | 0.190 |
Why?
| | Breast | 1 | 2022 | 138 | 0.190 |
Why?
| | Hypothalamus | 1 | 2022 | 147 | 0.180 |
Why?
| | Chromosomes, Human, Pair 11 | 2 | 2010 | 57 | 0.170 |
Why?
| | Humans | 37 | 2022 | 114043 | 0.170 |
Why?
| | Skin Neoplasms | 1 | 2006 | 754 | 0.160 |
Why?
| | Aged | 18 | 2019 | 18969 | 0.160 |
Why?
| | Vulva | 2 | 2022 | 24 | 0.160 |
Why?
| | Female | 26 | 2022 | 59325 | 0.160 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 140 | 0.160 |
Why?
| | Male | 25 | 2017 | 55396 | 0.160 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2010 | 308 | 0.160 |
Why?
| | Thymoma | 2 | 2011 | 29 | 0.150 |
Why?
| | Selenium | 2 | 2017 | 31 | 0.140 |
Why?
| | Adult | 17 | 2017 | 30375 | 0.140 |
Why?
| | Urinary Bladder | 1 | 2019 | 161 | 0.140 |
Why?
| | Bevacizumab | 1 | 2017 | 114 | 0.140 |
Why?
| | Erlotinib Hydrochloride | 1 | 2016 | 64 | 0.140 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2019 | 196 | 0.140 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 29 | 0.130 |
Why?
| | Disease-Free Survival | 4 | 2013 | 618 | 0.130 |
Why?
| | Neoplasm Staging | 4 | 2017 | 1162 | 0.130 |
Why?
| | Anilides | 1 | 2016 | 67 | 0.130 |
Why?
| | Carcinoma | 2 | 2011 | 198 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 152 | 0.130 |
Why?
| | Sputum | 1 | 2017 | 286 | 0.130 |
Why?
| | DNA Methylation | 2 | 2017 | 493 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2013 | 1142 | 0.120 |
Why?
| | Isotretinoin | 1 | 2014 | 22 | 0.120 |
Why?
| | Angiomatosis | 1 | 2013 | 4 | 0.110 |
Why?
| | Breast Diseases | 1 | 2013 | 20 | 0.110 |
Why?
| | Polyps | 1 | 2013 | 10 | 0.110 |
Why?
| | Vulvar Diseases | 1 | 2013 | 10 | 0.110 |
Why?
| | Adenoma, Oxyphilic | 1 | 2013 | 6 | 0.110 |
Why?
| | Pyridines | 1 | 2016 | 419 | 0.110 |
Why?
| | Receptors, Prostaglandin E, EP3 Subtype | 1 | 2013 | 2 | 0.110 |
Why?
| | Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 4 | 0.110 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2013 | 34 | 0.110 |
Why?
| | Genes, ras | 1 | 2013 | 91 | 0.110 |
Why?
| | Hyperplasia | 1 | 2013 | 163 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 211 | 0.110 |
Why?
| | Interferon-alpha | 1 | 2014 | 185 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2010 | 24 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2009 | 57 | 0.100 |
Why?
| | Smad Proteins | 1 | 2012 | 39 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 2 | 2009 | 55 | 0.100 |
Why?
| | Genetic Association Studies | 1 | 2013 | 339 | 0.090 |
Why?
| | Pneumonectomy | 3 | 2017 | 121 | 0.090 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 19 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 577 | 0.090 |
Why?
| | Autophagy | 1 | 2013 | 235 | 0.090 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 784 | 0.090 |
Why?
| | Immunoenzyme Techniques | 2 | 2016 | 192 | 0.090 |
Why?
| | Carboplatin | 1 | 2011 | 135 | 0.090 |
Why?
| | Lipid Metabolism | 1 | 2013 | 441 | 0.090 |
Why?
| | Chromosomes, Human, X | 1 | 2010 | 61 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 3 | 2008 | 2272 | 0.090 |
Why?
| | World Health Organization | 1 | 2010 | 101 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2013 | 459 | 0.080 |
Why?
| | Aged, 80 and over | 6 | 2013 | 6306 | 0.080 |
Why?
| | Tidal Volume | 1 | 2010 | 75 | 0.080 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2010 | 39 | 0.080 |
Why?
| | Positive-Pressure Respiration | 1 | 2010 | 68 | 0.080 |
Why?
| | Survival Analysis | 4 | 2017 | 1206 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 445 | 0.080 |
Why?
| | Reproducibility of Results | 4 | 2016 | 2764 | 0.080 |
Why?
| | Fibroma | 1 | 2009 | 21 | 0.080 |
Why?
| | Genes, p16 | 1 | 2009 | 16 | 0.080 |
Why?
| | Cell Dedifferentiation | 1 | 2009 | 28 | 0.080 |
Why?
| | Carcinoma, Renal Cell | 1 | 2010 | 168 | 0.070 |
Why?
| | Tissue Fixation | 2 | 2008 | 27 | 0.070 |
Why?
| | Collagen | 1 | 2009 | 414 | 0.070 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2006 | 16 | 0.070 |
Why?
| | Forkhead Box Protein O1 | 1 | 2006 | 15 | 0.070 |
Why?
| | Cytodiagnosis | 1 | 2006 | 29 | 0.070 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2008 | 176 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2010 | 324 | 0.070 |
Why?
| | Adenoma | 1 | 2008 | 187 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 155 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 1880 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 913 | 0.060 |
Why?
| | Gene Rearrangement | 1 | 2006 | 135 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 388 | 0.060 |
Why?
| | Pain Measurement | 1 | 2008 | 441 | 0.060 |
Why?
| | Rare Diseases | 1 | 2006 | 88 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2090 | 0.060 |
Why?
| | Coccidioides | 1 | 2004 | 4 | 0.060 |
Why?
| | Coccidioidomycosis | 1 | 2004 | 7 | 0.060 |
Why?
| | Epigenesis, Genetic | 1 | 2009 | 517 | 0.060 |
Why?
| | Shoulder Pain | 1 | 2004 | 32 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1257 | 0.060 |
Why?
| | Salivary Gland Neoplasms | 1 | 2004 | 31 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2009 | 445 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 1836 | 0.060 |
Why?
| | Mesothelioma | 1 | 2004 | 31 | 0.060 |
Why?
| | Taxoids | 1 | 2004 | 93 | 0.060 |
Why?
| | Osteosarcoma | 1 | 2004 | 65 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2017 | 9049 | 0.050 |
Why?
| | Fibroblasts | 1 | 2007 | 834 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 181 | 0.050 |
Why?
| | Tissue Array Analysis | 2 | 2013 | 48 | 0.050 |
Why?
| | Prognosis | 3 | 2016 | 3315 | 0.050 |
Why?
| | Fibroma, Desmoplastic | 1 | 2002 | 2 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 1791 | 0.050 |
Why?
| | Artifacts | 1 | 2003 | 114 | 0.050 |
Why?
| | Ribs | 1 | 2002 | 29 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 721 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 714 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 1875 | 0.040 |
Why?
| | Leukopenia | 2 | 2014 | 27 | 0.040 |
Why?
| | Fowlpox virus | 1 | 2019 | 1 | 0.040 |
Why?
| | Administration, Intravesical | 1 | 2019 | 14 | 0.040 |
Why?
| | Incidence | 2 | 2017 | 2314 | 0.040 |
Why?
| | Paraffin Embedding | 2 | 2010 | 21 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 1381 | 0.040 |
Why?
| | Phosphorylation | 2 | 2013 | 1558 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2006 | 1175 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 924 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4392 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1519 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 305 | 0.040 |
Why?
| | International Agencies | 1 | 2016 | 29 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 332 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 67 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1228 | 0.030 |
Why?
| | Adolescent | 4 | 2006 | 17800 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2010 | 1690 | 0.030 |
Why?
| | Chemotherapy-Induced Febrile Neutropenia | 1 | 2014 | 1 | 0.030 |
Why?
| | Early Termination of Clinical Trials | 1 | 2014 | 14 | 0.030 |
Why?
| | Cohort Studies | 2 | 2014 | 4883 | 0.030 |
Why?
| | Patient Selection | 1 | 2017 | 629 | 0.030 |
Why?
| | Carcinoma, Small Cell | 1 | 2014 | 158 | 0.030 |
Why?
| | Myxoma | 1 | 2013 | 11 | 0.030 |
Why?
| | Histocytochemistry | 1 | 2013 | 78 | 0.030 |
Why?
| | Alopecia | 1 | 2013 | 28 | 0.030 |
Why?
| | Genes, p53 | 1 | 2013 | 61 | 0.030 |
Why?
| | Chemoprevention | 1 | 2013 | 87 | 0.030 |
Why?
| | Constipation | 1 | 2013 | 75 | 0.030 |
Why?
| | Demography | 1 | 2013 | 258 | 0.030 |
Why?
| | Postoperative Period | 1 | 2013 | 288 | 0.030 |
Why?
| | Tamoxifen | 1 | 2013 | 190 | 0.030 |
Why?
| | Microscopy | 1 | 2013 | 125 | 0.030 |
Why?
| | Estrogen Receptor alpha | 1 | 2013 | 121 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1204 | 0.020 |
Why?
| | Longevity | 1 | 2013 | 137 | 0.020 |
Why?
| | Fatigue | 1 | 2013 | 294 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 356 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2014 | 489 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 845 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 521 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 813 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2384 | 0.020 |
Why?
| | Cetuximab | 1 | 2011 | 90 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2016 | 787 | 0.020 |
Why?
| | Child | 2 | 2006 | 18400 | 0.020 |
Why?
| | Estradiol | 1 | 2013 | 450 | 0.020 |
Why?
| | Pilot Projects | 1 | 2014 | 1360 | 0.020 |
Why?
| | Chromosome Aberrations | 1 | 2010 | 134 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2010 | 117 | 0.020 |
Why?
| | Homeostasis | 1 | 2013 | 570 | 0.020 |
Why?
| | Respiratory Mechanics | 1 | 2010 | 56 | 0.020 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2009 | 56 | 0.020 |
Why?
| | Karyotyping | 1 | 2009 | 100 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2011 | 370 | 0.020 |
Why?
| | Animals | 3 | 2019 | 31565 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 1656 | 0.020 |
Why?
| | Neoplasms, Adipose Tissue | 1 | 2009 | 1 | 0.020 |
Why?
| | Retinoblastoma Protein | 1 | 2009 | 52 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 863 | 0.020 |
Why?
| | Young Adult | 2 | 2013 | 10444 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 2010 | 218 | 0.020 |
Why?
| | Anesthesia | 1 | 2010 | 117 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 522 | 0.020 |
Why?
| | Connective Tissue Cells | 1 | 2007 | 2 | 0.020 |
Why?
| | Fixatives | 1 | 2007 | 15 | 0.020 |
Why?
| | Mitochondria | 1 | 2013 | 744 | 0.020 |
Why?
| | Formaldehyde | 1 | 2007 | 46 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2007 | 175 | 0.020 |
Why?
| | Stromal Cells | 1 | 2007 | 96 | 0.020 |
Why?
| | Swine | 1 | 2010 | 687 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2010 | 580 | 0.020 |
Why?
| | Specimen Handling | 1 | 2008 | 153 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2537 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 660 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 2698 | 0.020 |
Why?
| | Thymus Gland | 1 | 2007 | 296 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2173 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2009 | 385 | 0.020 |
Why?
| | Coronary Vessels | 1 | 2007 | 234 | 0.020 |
Why?
| | Preoperative Care | 1 | 2008 | 319 | 0.020 |
Why?
| | Phenotype | 1 | 2013 | 2784 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 787 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2014 | 12521 | 0.020 |
Why?
| | Oxygen | 1 | 2010 | 851 | 0.020 |
Why?
| | Hemodynamics | 1 | 2010 | 1015 | 0.020 |
Why?
| | Itraconazole | 1 | 2004 | 7 | 0.020 |
Why?
| | Metacarpus | 1 | 2004 | 5 | 0.010 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2004 | 6 | 0.010 |
Why?
| | Pneumonia | 1 | 2010 | 563 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2009 | 1131 | 0.010 |
Why?
| | Agranulocytosis | 1 | 2004 | 31 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 3397 | 0.010 |
Why?
| | Antifungal Agents | 1 | 2004 | 128 | 0.010 |
Why?
| | Edema | 1 | 2004 | 119 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2004 | 134 | 0.010 |
Why?
| | Skin | 1 | 2007 | 653 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 370 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2004 | 221 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2010 | 2550 | 0.010 |
Why?
| | Cytokines | 1 | 2010 | 1824 | 0.010 |
Why?
| | Radiography | 1 | 2004 | 803 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1024 | 0.010 |
Why?
| | Survival Rate | 1 | 2004 | 1638 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4501 | 0.010 |
Why?
| | Health Status | 1 | 2004 | 716 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1468 | 0.010 |
Why?
| | Lung | 1 | 2010 | 3521 | 0.010 |
Why?
| | Mice | 1 | 2013 | 14841 | 0.010 |
Why?
| | United States | 1 | 2004 | 12137 | 0.000 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|